BIIB-104
BIIB-104 (also known as AMPX-0079) is a novel, orally administered, small molecule drug that is being developed by Biogen for the treatment of Parkinson's disease and Alzheimer's disease. It is currently in the clinical trial phase.
Mechanism of Action[edit | edit source]
BIIB-104 works by modulating the activity of the AMP-activated protein kinase (AMPK) pathway. This pathway is involved in the regulation of cellular energy homeostasis and has been implicated in the pathogenesis of several neurodegenerative diseases, including Parkinson's and Alzheimer's.
Clinical Trials[edit | edit source]
BIIB-104 is currently being evaluated in Phase 2 clinical trials for the treatment of Parkinson's disease and Alzheimer's disease. The drug has shown promising results in early-stage trials, with improvements in cognitive function and motor symptoms observed in patients with these conditions.
Potential Benefits[edit | edit source]
The potential benefits of BIIB-104 include its oral administration, which makes it easier to use than injectable treatments, and its targeted mechanism of action, which could result in fewer side effects than existing treatments. Furthermore, if successful, BIIB-104 could provide a new treatment option for patients with Parkinson's and Alzheimer's, diseases for which there are currently limited treatment options.
Safety and Side Effects[edit | edit source]
As with any drug, BIIB-104 has potential side effects. These are currently being evaluated in ongoing clinical trials. Early results suggest that the drug is well-tolerated, with few serious side effects reported.
Future Directions[edit | edit source]
The future of BIIB-104 depends on the results of ongoing clinical trials. If these trials are successful, the drug could be approved for use in patients with Parkinson's and Alzheimer's disease. Further research is also needed to fully understand the mechanism of action of BIIB-104 and to explore its potential use in other neurodegenerative diseases.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
